184 related articles for article (PubMed ID: 30633423)
1. Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature.
Beckham TH; Leeman J; Jillian Tsai C; Riaz N; Sherman E; Singh B; Lee N; McBride S; Higginson DS
Head Neck; 2019 May; 41(5):1418-1426. PubMed ID: 30633423
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Fanconi Anemia Patients with Head and Neck Squamous Cell Carcinoma: Israel Fanconi Registry.
Tsur N; Frig O; Steinberg-Shemer O; Tamary H; Kurman N; Mizrachi A; Popovtzer A
Isr Med Assoc J; 2022 Aug; 24(8):491-496. PubMed ID: 35971997
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and individual patient data analysis of pediatric head and neck squamous cell carcinoma: An analysis of 217 cases.
Bhanu Prasad V; Mallick S; Upadhyay AD; Rath GK
Int J Pediatr Otorhinolaryngol; 2017 Jan; 92():75-81. PubMed ID: 28012539
[TBL] [Abstract][Full Text] [Related]
4. Natural history and management of Fanconi anemia patients with head and neck cancer: A 10-year follow-up.
Kutler DI; Patel KR; Auerbach AD; Kennedy J; Lach FP; Sanborn E; Cohen MA; Kuhel WI; Smogorzewska A
Laryngoscope; 2016 Apr; 126(4):870-9. PubMed ID: 26484938
[TBL] [Abstract][Full Text] [Related]
5. Squamous cell carcinoma of the oral tongue in a patient with Fanconi anemia treated with radiotherapy and concurrent cetuximab: a case report and review of the literature.
Wong WM; Parvathaneni U; Jewell PD; Martins RG; Futran ND; Laramore GE; Liao JJ
Head Neck; 2013 Oct; 35(10):E292-8. PubMed ID: 22965917
[TBL] [Abstract][Full Text] [Related]
6. Management of Fanconi Anemia patients with head and neck carcinoma: Diagnosis and treatment adaptation.
Beddok A; Krieger S; Castera L; Stoppa-Lyonnet D; Thariat J
Oral Oncol; 2020 Sep; 108():104816. PubMed ID: 32480311
[TBL] [Abstract][Full Text] [Related]
7. Successful use of a therapeutic trial of graduated volume and dose escalation for postoperative head and neck radiotherapy in a Fanconi anemia patient.
Lewis LM; Tang AL; Wise-Draper TM; Myers KC; Greenberger JS; Takiar V
Head Neck; 2020 Oct; 42(10):E16-E22. PubMed ID: 32770810
[TBL] [Abstract][Full Text] [Related]
8. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia.
Kutler DI; Auerbach AD; Satagopan J; Giampietro PF; Batish SD; Huvos AG; Goberdhan A; Shah JP; Singh B
Arch Otolaryngol Head Neck Surg; 2003 Jan; 129(1):106-12. PubMed ID: 12525204
[TBL] [Abstract][Full Text] [Related]
9. Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines.
Scheckenbach K; Wagenmann M; Freund M; Schipper J; Hanenberg H
Klin Padiatr; 2012 Apr; 224(3):132-8. PubMed ID: 22504776
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
Lee RH; Kang H; Yom SS; Smogorzewska A; Johnson DE; Grandis JR
Clin Cancer Res; 2021 Oct; 27(19):5168-5187. PubMed ID: 34045293
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
12. Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck.
Awan MJ; Nedzi L; Wang D; Tumati V; Sumer B; Xie XJ; Smith I; Truelson J; Hughes R; Myers LL; Lavertu P; Wong S; Yao M
Ann Oncol; 2018 Apr; 29(4):998-1003. PubMed ID: 29346519
[TBL] [Abstract][Full Text] [Related]
13. Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma.
Mroz EA; Patel KB; Rocco JW
Cancer; 2020 Jan; 126(9):1895-1904. PubMed ID: 32083741
[TBL] [Abstract][Full Text] [Related]
14. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
Chandrasekharappa SC; Chinn SB; Donovan FX; Chowdhury NI; Kamat A; Adeyemo AA; Thomas JW; Vemulapalli M; Hussey CS; Reid HH; Mullikin JC; Wei Q; Sturgis EM
Cancer; 2017 Oct; 123(20):3943-3954. PubMed ID: 28678401
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Comorbidities among Older Head and Neck Cancer Survivors in the United States.
Eytan DF; Blackford AL; Eisele DW; Fakhry C
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):85-92. PubMed ID: 30252608
[TBL] [Abstract][Full Text] [Related]
16. Head and neck squamous cell carcinoma of unknown primary: Outcomes of a pre-defined institutional treatment policy in a region with a high prevalence of skin cancer.
Huo M; Panizza B; Bernard A; Porceddu SV
Oral Oncol; 2018 Feb; 77():43-48. PubMed ID: 29362125
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
[TBL] [Abstract][Full Text] [Related]
18. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
19. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
Zandberg DP; Cullen K; Bentzen SM; Goloubeva OG
Oral Oncol; 2018 Nov; 86():132-140. PubMed ID: 30409293
[TBL] [Abstract][Full Text] [Related]
20. Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience.
Gandhi AK; Roy S; Biswas A; Raza MW; Saxena T; Bhasker S; Sharma A; Thakar A; Mohanti BK
Auris Nasus Larynx; 2016 Feb; 43(1):45-9. PubMed ID: 26165629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
